Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

Core Insights - Alterity Therapeutics has appointed Dr. Daniel O. Claassen as Chief Medical Advisor, effective March 2026, bringing extensive expertise in neurodegenerative diseases to the company [1][3] Company Overview - Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Multiple System Atrophy (MSA) [4] - The company is preparing to initiate a Phase 3 pivotal trial for its lead asset, ATH434, which has shown clinically meaningful efficacy in Phase 2 trials [4] Dr. Claassen's Background - Dr. Claassen is a board-certified neurologist with over 20 years of experience in clinical and translational research related to movement disorders and cognitive neurology [2] - He has authored hundreds of peer-reviewed publications and has been a principal investigator in numerous clinical trials, contributing significantly to the advancement of therapies for neurodegenerative disorders [2] Strategic Importance - The appointment of Dr. Claassen is seen as pivotal for Alterity as it advances ATH434 into Phase 3 trials, with his previous involvement in the Phase 2 study enhancing his qualifications to guide the company's growth [3] - Dr. Claassen's focus on translating academic research into clinical applications aligns with the urgent need for disease-modifying therapies in neurodegenerative diseases [3]